BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 23015417)

  • 21. [TET proteins and epigenetic modifications in cancers].
    Ciesielski P; Jóźwiak P; Krześlak A
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1371-83. PubMed ID: 26671928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.
    Fernandez-Pol S; Ma L; Joshi RP; Arber DA
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):416-422. PubMed ID: 29629950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of epigenetic changes in hematological malignancies.
    Lehmann U; Brakensiek K; Kreipe H
    Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetics in Hematological Malignancies.
    Cruz-Rodriguez N; Combita AL; Zabaleta J
    Methods Mol Biol; 2018; 1856():87-101. PubMed ID: 30178247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TET2 in Normal and Malignant Hematopoiesis.
    Bowman RL; Levine RL
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28242787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies.
    Li W; Xu L
    Oncol Res Treat; 2019; 42(6):309-318. PubMed ID: 31055566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.
    Reszka E; Jabłońska E; Wieczorek E; Valent P; Arock M; Nilsson G; Nedoszytko B; Niedoszytko M
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
    Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
    Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Epigenetic therapy for hematologic malignancies].
    Kobayashi Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.
    Yeh CH; Bai XT; Moles R; Ratner L; Waldmann TA; Watanabe T; Nicot C
    Mol Cancer; 2016 Feb; 15():15. PubMed ID: 26880370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
    Zhang SJ; Abdel-Wahab O
    Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
    Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
    Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
    Zhang P; Zhang M
    Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
    Soura EN; Karikas GA
    J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetics in the hematologic malignancies.
    Fong CY; Morison J; Dawson MA
    Haematologica; 2014 Dec; 99(12):1772-83. PubMed ID: 25472952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
    Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
    PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
    Vainchenker W; Kralovics R
    Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetics of hematopoiesis and hematological malignancies.
    Hu D; Shilatifard A
    Genes Dev; 2016 Sep; 30(18):2021-2041. PubMed ID: 27798847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The many layers of epigenetic dysfunction in B-cell lymphomas.
    Jiang Y; Dominguez PM; Melnick AM
    Curr Opin Hematol; 2016 Jul; 23(4):377-84. PubMed ID: 27055146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.